UBS Group
SGMT icon

UBS Group’s Sagimet Biosciences SGMT Stock Holding History

UBS Group’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.63M Buy
339,930
+45,996
+16% +$313K ﹤0.01% 4848
2026
Q1 		$1.54M Buy
293,934
+92,175
+46% +$514K ﹤0.01% 5204
2025
Q4 		$1.19M Sell
201,759
-105,007
-34% -$754K ﹤0.01% 5423
2025
Q3 		$2.1M Sell
306,766
-265,969
-46% -$2.16M ﹤0.01% 4895
2025
Q2 		$4.36M Buy
572,735
+94,305
+20% +$398K ﹤0.01% 4026
2025
Q1 		$1.56M Buy
478,430
+145,270
+44% +$609K ﹤0.01% 4908
2024
Q4 		$1.5M Buy
333,160
+191,895
+136% +$972K ﹤0.01% 4983
2024
Q3 		$391K Buy
141,265
+44,893
+47% +$138K ﹤0.01% 5399
2024
Q2 		$330K Buy
96,372
+33,236
+53% +$152K ﹤0.01% 5312
2024
Q1 		$342K Buy
63,136
+43,148
+216% +$310K ﹤0.01% 5475
2023
Q4 		$108K Buy
19,988
+16,997
+568% +$80.2K ﹤0.01% 6127
2023
Q3 		$26.3K Buy
+2,991
New +$39.8K ﹤0.01% 6660

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group's SGMT Position: Q2 2026 in Review

UBS Group increased its Sagimet Biosciences (SGMT) stake by 16% in Q2 2026, buying an estimated $313K and bringing the position to 339,930 shares worth $2.63M. The position accounts for ﹤0.01% of the portfolio, ranked #4848.

UBS Group first reported a position in SGMT in Q3 2023 and has held it in 12 quarters since. The position peaked at $4.36M in Q2 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • UBS Group held 339,930 shares of Sagimet Biosciences worth $2.63M as of Q2 2026.
  • UBS Group bought 45,996 Sagimet Biosciences shares in Q2 2026, an estimated $313K.
  • Sagimet Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4848 holding.
  • UBS Group first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 12 quarters since.
  • UBS Group's Sagimet Biosciences position peaked at $4.36M in Q2 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.